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1. Abstract 
 
 Important to the world of pharmacology and drug discovery is the process of 
pharmacokinetic modeling. This part of the process gives developers and clinicians a basis of 
knowledge on how a drug moves through the body. This project focuses on three types of 
models: non-compartmental analysis, nonlinear mixed-effects models, and physiologically-based 
pharmacokinetic models. Each model differs in complexity and varies in the information it can 
provide. With an understanding of each type of model and an overview of the functions each 
serves, two drugs are examined in this project. The data collectors working on each project 
identified the level of modeling, i.e. the types of models they wanted for their drug. 
 The first is a drug called Tulathromycin. The data collectors on this project requested 
non-compartmental analysis. This individual project served largely as an introduction to the 
process of modeling and the programs that were required at each step. Following Tulathromycin, 
a second project was completed with a drug called Flunixin Meglumine. It was requested that 
nonlinear mixed-effects models be created for this drug. This second project expounded upon the 
knowledge gained in the Tulathromycin project, and went further to create a more complex 
model that gave the data collectors more freedom and knowledge about how the drug could be 
applied. The process of selecting a model and the criteria used by the programs for selection is 
reported and discussed in the section for Flunixin Meglumine. 
 Finally, this overall project examined a real-life application of pharmacokinetic models in 
order to provide perspective of their use. Neither model that was worked with hands-on used the 
observations for predictive models, so it is central that a common application like this was 
examined. Overall, models like these are central in allowing clinical observations to pave the 
way for knowledgeable dosing regimens in animals. These models are used by clinicians to 
predict the recommended administration amount and method, and allow them to take in 
covariates of the subject they are working with. The predictive knowledge informs confident and 
safe dosing strategies in the world of medicine and pharmacology. 
 
2. Introduction 
 
Pharmacokinetic models have a multitude of applicative uses, and they are often a 
fundamental part of clinical trials. They can be used to inform dosing strategies, enhance multi-
drug administration, and identify covariates of an animal that may affect how it responds to a 
drug. While there are also various types of pharmacokinetic models, each method has its 
importance in giving desired information on a drug. Thus, modeling techniques can be chosen by 
identifying the simplest model that is able to give the requested information. Three models were 
discussed throughout the course of this project, and the brief analysis of each to follow gives 
insight as to which model is best for the desired outcome. 
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 One of the simplest models to describe the pharmacokinetics of a drug is non-
compartmental analysis. With data that has information on the concentration of the drug in the 
body over time for each individual in the study; this type of model works to explain the drug in 
its simplicity, that is, how it is being absorbed, how it is being eliminated, and the total amount 
of the drug that makes its way into and out 
of the body.  Figure 1, to the left, shows a 
typical drug concentration curve. In 
performing non-compartmental analysis, 
programs are analyzing the different phases 
of the graph to obtain parameters. The first 
phase is the absorption phase, characterized 
by an increase of the drug in the body. This 
is due to the fact that the absorption rate 
multiplied by the amount of drug available 
for absorption is larger than the elimination 
rate multiplied by the amount of drug in the 
body (Jambhekar & Breen, 2012). These 
values reach an equilibrium, and then the 
elimination phase of the curve is observed. In contrast to the absorption phase, the elimination 
phase is characterized by the value of the elimination rate multiplied by the amount of drug in 
the body being larger than the value of the absorption rate multiplied by the amount of drug 
available for absorption (Jambhekar & Breen, 2012). Using these phases, and changes in the 
curve over time, the program is able to give parameters that describe the pharmacokinetics of the 
drug. 
 The second model gives greater insight as to how the drug is moving within the body, 
and details from nonlinear mixed-effects (NLME) models can be used to extrapolate the 
collected data to situations that have not yet been tested. These models not only seek to explain 
the same parameters as the non-compartmental analysis, but also aim to describe how the drug is 
moving within the individual after being absorbed and before being excreted. Similar to non-
compartmental analysis, NLME models require repeated measurements of a response, and often 
this is in the form of concentration measurements taken over time. These types of models split 
the body into compartments, and use ordinary differential equations (ODEs) to describe how 
these drugs move between the compartments (Davidian, 2004). These ODEs are informed by the 
parameters estimated by the program being used to create the models (Davidian, 2004). After 
creating an accurate model, these parameter estimates and mathematical equations can be used 
for predictive studies of tests that have not yet been performed (Davidian, 2004).  
 The final model discussed in this project was not worked with directly, and thus, will 
only be explained briefly. These models are called physiologically-based pharmacokinetic 
(PBPK) models. They have applications in attempting to explain why a drug behaves within the 
body the way it does. PBPK models take into consideration the physiological pathways in the 
body that are directly influenced by the drug (Sun et al., 2020). In this way, understanding how 
the physiology of the body behaves normally, and how it responds to covariates like illness, age 
weight, etc., come together to model how the drug behaves in the body under normal conditions 
and how it changes when these conditions are altered (Sun et al., 2020). Put simply, they are 
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beneficial because they work to explain the pharmacokinetics of a drug rather than merely 
modeling the observed effects or predicting outcomes based on the observed effects. 
 The two drugs directly examined in this project are Tulathromycin and Flunixin 
Meglumine. The first part of the project centered around Tulathromycin. This is an antibiotic 
used to treat respiratory bacterial pathogens (Clothier, 2010). The second part of the project, and 
the more extensive part, focused on Flunixin Meglumine. Flunixin Meglumine is a non-steroidal 
anti-inflammatory drug used in veterinary medicine, often for the treatment of pain and 
inflammation (Huber et al., 2013). While both projects centered around modeling the drugs, 
there were separate goals for each. Completing a non-compartmental analysis was the goal for 
Tulathromycin, and creating a NLME model was the goal for Flunixin Meglumine. The methods 
section to follow examines the process for each drug. 
 
3. Methods 
 
The pharmacokinetic modeling of both projects took on a framework of three phases; in 
order, the phases were data exploration, non-compartmental analysis, and nonlinear mixed-
effects modeling. Each phase of the modeling process served an essential purpose to aid in 
further steps. Below, the phases of pharmacokinetic modeling are discussed in further detail, and 
then applied to separate modeling projects relating to the aforementioned drugs. 
Data exploration was the first phase of modeling because it gave the modeler the 
opportunity to become familiar with the data and work it into a usable format. R Studio was the 
data exploration software used for the two separate projects. It is a statistical modeling software 
that allows for modification and early visualization of data. In both cases, the data received for 
the project was not presented in an acceptable format for the programs used later in the modeling 
process. Thus, coding in R Studio largely consisted of steps to correct inconsistencies in the data 
entry, and to modify the data so that each subsequent program had the information needed to 
perform the required analysis. Once the data was in an acceptable form for moving forward, the 
final step was to graph the data in R Studio, stratifying by individual, to get an initial look at the 
drug concentration graphs. This served to identify any outliers in the data and to make sure the 
concentration curves were presenting in a way that made sense for the movement of a drug 
within the body. 
Following the data exploration phase, non-compartmental analysis was another partial 
phase of data exploration, but additionally served to give initial estimates of parameters that 
would be used later in the process of building a pharmacokinetic model. The program PKanalix, 
a product made by Lixoft, was used for this part of the project. Once the data was uploaded into 
the program, non-compartmental analysis was performed to give further information about the 
drug. For non-compartmental analysis, the program works to calculate the slope of the terminal 
elimination phase. This is represented by the variable λz, and if this value can be calculated, the 
program can calculate and report non-compartmental analysis parameters that are extrapolated to 
infinity (PKanalix documentation, n.d.). These parameters are useful in the next phase of 
creating a pharmacokinetic model. 
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The final phase of pharmacokinetic modeling is the phase consisting of building a 
representative model of the data. The models used in this project were nonlinear-mixed effects 
models, which were built in a program called Monolix, another program made by Lixoft. This 
phase of the project used initial parameters estimated by the previous phase to build a model to 
best fit the data. The models that are built into the program center around three different types: 
one compartment, two compartment, and three compartment models. These models are nested, 
that is, each subsequent model draws information from the previous. The one compartment 
model has a central compartment, the two compartment model has a central compartment with 
an additional peripheral compartment, and the three compartment model has a central 
compartment and two peripheral compartments. Monolix gives a likelihood associated with each 
model to describe the fit, and this parameter is partially informed by the Bayesian information 
criterion (Monolix documentation, n.d.). This is a mathematical process that focuses on choosing 
the lowest dimensional model while still capturing the data presented. In this way, regardless of 
increased information, this criterion still picks the lowest dimensional model to fit the data (The 
Bayes Information Criterion, n.d.). Once the best-fit model is identified, Monolix gives the 
option to explore various interfaces that give information about how well the selected model fits 
the data, and also allows for the analysis of covariates and their influence on the parameters of 
the model. 
 
3.1. Tulathromycin 
 
The outline given above was applied to two drugs in this project. The first was a drug 
called Tulathromycin. The goal of this project was to perform non-compartmental analysis on 
this drug, and it served largely as a learning tool of the programs that were mentioned above. The 
data set was a measurement of five tissue concentrations taken with respect to time in ewes. The 
data presented initially was not in a readable form for the programs, so the data exploration 
phase consisted mainly of learning the coding in R Studio to modify the data into a 
comprehensible form. One of the largest components of this phase was learning how to add an 
amount column to the data based on the information of dosing that was given. Once this was 
achieved, the data was graphed in R Studio, and stratified by the individuals, in order to allow for 
an initial look at the concentration curves with respect to time. These graphs were examined, and 
any identifiable outliers were addressed or removed. 
From this point, the Tulathromycin project was fit for analysis in PKanalix. Uploading 
the data into the program gave a second look at the data which served as a brief, additional data 
exploration phase. After deeming all of the graphs fit for further analysis, the non-compartmental 
analysis was run through the program. The largest step of this phase was allowing the program to 
estimate the slope of the terminal elimination phase, as mentioned above, which allowed for the 
extrapolation estimates of parameters. At this point in the project, the analysis for Tulathromycin 
was complete with respect to what the data collectors had requested. 
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3.2. Flunixin Meglumine 
 
After working with Tulathromycin and learning many of the skills required for 
pharmacokinetic modeling, a larger project that covered all three of phases of modeling was 
presented. This project centered around the drug Flunixin Meglumine (FM). The goal of this 
modeling project was to use nonlinear mixed-effects models to create an accurate 
pharmacokinetic model for the drug. This drug followed similar steps as the project above. The 
first goal was to complete the data exploration phase. Data for this project had been collected 
from three different people, all with various methods of data entry. Thus, the data exploration 
phase consisted largely of remedying the different data entry inconsistencies, and then 
combining the three separate data reports into one readable table for the programs to follow. 
When the data was acceptably formatted, the concentration versus time plots were created for 
each individual to give an initial look and ensure the curves made sense with what was expected 
for a pharmacokinetic concentration curve over time. At this stage in the process, the data was 
ready for non-compartmental analysis. 
The goal of the FM project, unlike the Tulathromycin project, was to create a nonlinear 
mixed-effects model. Therefore, not only did the analysis in PKanalix serve as a secondary data 
exploration, but the parameter estimates were then also used in the actual making of a 
pharmacokinetic model. PKanalix was able to estimate the slope of the terminal elimination 
phase, and then report the necessary parameters for the initial estimates for the model. Once 
these were obtained, the data was uploaded into Monolix, where it underwent the initial stages of 
finding a suitable model. Three candidate models were made for the data: a one compartment 
model, a two compartment model, and a three compartment model. Each was a base-model for 
the data, and the next step of model building would require the identification of the best model 
out of the three, and then further modification of this model to better fit it to the data. At this time 
in the project, a meeting was held with the data collectors in order to provide an update on the 
status of the FM project, and to give a few initial parameter estimates that were obtained from 
the non-compartmental analysis. During this meeting, it was discovered that a few 
inconsistencies in the data had been overlooked originally, and needed to be re-addressed. Most 
notably, there were inconsistencies used in data entry relating to the dose and dosage columns, 
and there was a discontinuity with the way different data collectors entered the values for 
covariates of the animals. These inconsistencies needed to be rectified in order to move forward 
with the model building. 
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The project began back where it had left off at the data exploration phase after these 
problems were identified. Once these 
various discontinuities were addressed 
within the data, it was again uploaded to 
PKanalix for the calculation of the slope of 
the terminal elimination phase, and again 
the program gave initial parameter 
estimates. Moving forward to making 
model candidates, it was ultimately 
identified that a two compartment model 
had the highest likelihood. A schematic of 
the two compartment model can be found in 
Figure 2, right. This candidate was chosen 
to move forward for further modification in 
order to make a more accurate model. 
Various goodness-of-fit diagnostic plots are 
included in the results section below to 
demonstrate the models correlation with the 
observed data. 
 
 
4. Results 
 
4.1 Tulathromycin 
 
 In PKanalix, the slope of the terminal 
elimination phase was successful for 
Tulathromycin. Thus, λz was extrapolated to 
infinity and the program was able to report 
parameter estimates; these values can be found 
in Table 1, right. Additionally, these 
parameter estimates gave information on 
making lines of best fit for each individual. A 
sampling of the individual plots with the lines 
of best fit are given in Figure 3, below. While 
there were parameter estimates that could be reported, after further examination of the data was 
ultimately not as useful as hoped. The parameters were still reported back to the data collectors 
along with a cautionary message about the viability of the data. 
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4.2 Flunixin Meglumine 
 
 Flunixin Meglumine, along with reporting parameter estimates from the NLME, were 
examined for goodness-of-fit to describe the level of accuracy of the predictive model. The 
parameter estimates can be found in Table 2 below. 
 
The parameter estimates given in Table 2 are the same parameter estimates given from the non-
compartmental analysis for Tulathromycin; however, because FM was best modeled with a two 
compartment model, unlike Tulathromycin, it has two reported volume concentrations. 
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 To examine how well this two compartment model fit the data, two separate goodness-of-
fit tests were examined. The first test 
consisted of graphs, stratified by 
individual, that showed a visual 
representation of how well the 
population parameters matched the 
observed data for the individuals 
(Monolix documentation, n.d.). 
Figure 3 shows a group of twelve 
individual fits. It can be seen that in 
most of the individuals in the figure, 
both the curve of best fit and the 
population fit on the individual 
parameters have similarities in shape 
and are sometimes overlapping. 
There are three individuals in the 
figure, namely 147#5, 157#5, and 
163#5, that appear to have disparities 
between the lines shown in the 
individual fit plots. 
The second goodness-of-fit test was a graphical depiction of the residuals, shown in 
Figure 4. The residuals were measured in two different ways. The population weighted residual 
(PWRES) graph consists of residuals measured by comparing the observed data and the 
estimated population parameters. The individual weighted residual (IWRES) graph consists of 
residuals measured by comparing the observed data and the estimated individual parameters 
(Monolix documentation, n.d.). As expected, there is a larger variation for residuals of the 
PWRES graph versus the IWRES graph. Overall, the condensed plots, showing a small number 
of outliers, indicate that the model was fitted well to the observed data. 
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 Although the goodness-of-fit tests completed for the NLME model for FM show a large 
degree of accuracy, this project did not extend to predictive models of the drug’s actions in other 
scenarios. Because of this, a brief explanation of the real-life applications of these models was 
explored in a report that discussed the use of PBPK models in testing for drug interactions during 
coadministration. This study focused on olanzapine, an antipsychotic drug used for the treatment 
of schizophrenia. This drug often comes with an undesirable side effect of weight gain, so it is a 
good candidate for combining an alternative therapy to counteract the side effect. Samidorphan, 
an opiate, has the potential to restrain weight gain accompanying the administration of 
olanzapine (Sun et al., 2020). This study aimed at making a model for the coadministration of 
olanzapine and samidorphan. Researchers created separate PBPK models for each drug and their 
physiological profile based on observations from studies already completed. When accurate 
model candidates were created, researchers combined the PBPK models into a single model that 
focused on the coadministration of olanzapine and samidorphan (Sun et al., 2020). Using this 
model, they completed 10 virtual trials of 24 healthy subjects to examine the physiological 
interaction of the two drugs. They later examined adverse habits, like smoking, that had the 
potential to influence the associated physiological pathways and influence the drug interactions. 
In the end, this study found there to be no pharmacokinetic interaction between the two drugs 
(Sun et al., 2020). However, these PBPK models give a first hand look at the way they can 
change the process of drug design and reduce the cost and length of the drug discovery process; 
by using the correct tools, other models, too, have the potential to influence pharmacology in this 
way. (Fogler & Gurmen, 2007) 
Common between all of these projects are the models and the information they are 
conveying. The method discussed first, non-compartmental analysis, is often good for an initial 
examination of a drug profile. It also serves to give early parameter estimates that in and of 
themselves are useful for early drug discovery and information, but also serve to inform later 
models if desired. The second type of models, nonlinear mixed-effect models, build upon non-
compartmental analysis to form a wholistic picture of the pharmacokinetics of a drug. Not only 
can they describe more in-depth parameters like how the drug is moving between compartments 
in the body, but it can also take the estimated parameters to create predictive models for drug 
administration. The value of predictive models comes in describing outcomes that have not yet 
been tested. In this way, they can save time and costs that would normally needed to be spent on 
large-scale clinical trials and focus on predicting these virtually. Similar to the predicitive sense 
of nonlinear mixed-effect models, PBPK models can predict how drugs will behave in the body. 
In addition, PBPK models can serve to explain why a certain behavior is seen. These models 
focus on the underlying physiology with which the drug is interacting. Thus, identifying the 
correct physiological pathway and making an accurate drug model can give insight to 
interactions that the other types of models cannot detect. In short, each of these models serve 
varying degrees of purpose, and the correct identification of desired information can lead to the 
selection of the model that is best for each drug. This type of work allows for simple, informed 
profiles for the drugs that are under examination. 
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